Pancreatic Cancer

The FDA granting orphan drug designation to a pancreatic cancer product was one of the top stories in hematology and oncology last week.

The FDA approved olaparib as maintenance treatment for adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic cancer, according to a press release from the drug’s manufacturer.

The FDA granted orphan drug designation to the antibody-drug conjugate OBI-999 for the treatment of pancreatic cancer, according to a press release from the agent’s manufacturer.

SAN ANTONIO — Endoscopic ultrasound radiofrequency ablation had high technical and clinical success in the treatment of patients with pancreatic tumors, according to study results presented at the American College of Gastroenterology Annual Meeting.

Researchers at The University of Texas at Austin have developed a handheld device, known as the MasSpec Pen, designed to distinguish between cancerous and healthy tissue within seconds while in the operating room, according to a press release.

The top story in hematology/oncology last week discussed the importance of using simple, common language while communicating with patients to help them understand their cancer treatment.

A phase 3 trial designed to assess an investigational drug for first-line treatment of metastatic pancreatic cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.

African American and Hispanic patients who underwent pancreatectomy for pancreatic cancer appeared less likely than their white counterparts to utilize hospice services more than 3 days before death, according to results of a retrospective study scheduled for presentation at Supportive Care in Oncology Symposium.

A global study that spanned nearly 30 years in 195 countries has revealed different shifts in the trend of incidence and death rates of several gastrointestinal cancers, as well as the global burden of inflammatory bowel disease, according to data presented at UEG Week.

A randomized phase 3 trial that evaluated the addition of pegilodecakin to FOLFOX for treatment of metastatic pancreatic cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.